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Stromal–epithelial interactions dictate prostate tumori-
genesis and response to castration. Hydrogen peroxide-
inducible clone 5 (Hic-5/ARA55) is a transforming growth
factor-beta (TGF-b)-induced coactivator of androgen
receptor (AR) expressed in the prostate stroma. Interest-
ingly, following castration, we identiﬁed epithelial expres-
sion of Hic-5/ARA55 in mouse and human prostate
tissues. To determine the role of epithelial Hic-5 in
prostate cancer progression and castration responsiveness,
we compared LNCaP cells having Hic-5 stably expressed
with the parental LNCaP cells following tissue recombi-
nation xenografts with mouse prostate stromal cells. We
previously identiﬁed knocking out prostate stromal TGF-b
signaling potentiated castrate-resistant prostate tumors,
in a Wnt-dependent manner. The LNCaP chimeric tumors
containing prostate ﬁbroblasts conditionally knocked out
for the TGF-b type II receptor (Tgfbr2-KO) resulted in
larger, more invasive, and castration-resistant tumors
compared those with ﬂoxed (control) stromal cells.
However, the LNCaP-Hic5 associated with Tgfbr2-KO
ﬁbroblasts generated chimeric tumors with reduced tumor
volume, lack of invasion and restored castration depen-
dence. Neutralization of canonical Wnt signaling is shown
to reduce prostate tumor size and restore regression
following castration. Thus, we hypothesized that epithelial
Hic-5/ARA55 expression negatively regulated Wnt signal-
ing. The mechanism of the Hic-5/ARA55 effects on
castration was determined by analysis of the c-myc
promoter. C-myc luciferase reporter activity suggested Hic-
5/ARA55 expression inhibited c-myc activity by b-catenin.
Sequential ChIP analysis indicated b-catenin and T-cell-
speciﬁc 4 (TCF4) bound the endogenous c-myc promoter in
the absence of Hic-5 expression. However, the formation of a
TCF4/Hic-5 repressor complex inhibited c-myc promoter
activity, by excluding b-catenin binding with TCF4 on the
promoter. The data indicate Hic-5/ARA55 expression in
response to castration-enabled epithelial regression through
the repression of c-myc gene at the chromatin level.
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Introduction
Prostate cancer is the most commonly diagnosed cancer
and is increasing with the expanding aging population.
As the prostate is an androgen-dependent organ,
various methods of androgen depletion have therapeutic
beneﬁt for prostate cancer. However, castrate-resistant
prostate cancer is common and is the second leading
cause of cancer-related death in men in the United
States (Jemal et al., 2009). The microenvironment has a
critical role in the emergence and progression of prostate
cancer. Cancer-associated ﬁbroblasts contribute to the
progression of prostate and other epithelial cancers
(Chung et al., 2005; Hwang et al., 2008; Taylor and
Risbridger, 2008). In a reciprocal manner, paracrine
signals from the epithelial compartment contribute to
stromal differentiation (Mukaratirwa et al., 2005; Kass
et al., 2007; Cunha, 2008). The prostate stromal cells,
like the prostate luminal epithelia, express androgen
receptor (AR) and depend on androgens for growth,
survival and differentiation (Cunha, 2008). However, on
androgen depletion, such as through castration, the
stromal compartment regresses only a fraction of the
epithelial compartment (Uke et al., 1983; Johansson
et al., 2007; Placencio et al., 2008). Androgen signaling
of the prostate stroma is identiﬁed as a mediator for
epithelial androgen responsiveness (Cunha, 2008;
Kurita et al., 2001). More recently, transforming growth
factor-beta (TGF-b) responsiveness of the stromal
ﬁbroblasts was observed to enable prostate epithelial
regression following castration (Placencio et al., 2008).
A better understanding of stromal–epithelial interac-
tions is emerging to be especially critical for the
regulation of prostate cancer progression and castrate
resistance.
The prostate requires androgens in development for
proliferation and differentiation. Androgens are shown
to be important in maintaining prostate epithelial
quiescence following maturation (Niu et al., 2008).
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www.nature.com/oncHowever, it is less clear what enables prostate regression
in the absence of androgens. A mouse model with a
conditional stromal knockout of the TGF-b type II
receptor (Tgfbr2
fspKO) indicates the stromal ﬁbroblasts
contribute to prostate tumor initiation, progression, and
responsiveness to androgens (Bhowmick et al., 2004;
Placencio et al., 2008). The knockout TGF-b respon-
siveness of stroma resulted in the constitutive expression
of Wnt ligands, including Wnt3a, from the stroma
stimulating epithelial Wnt target genes (Li et al., 2008).
The canonical Wnt pathway is associated with the
stabilization and binding of b-catenin with the lymphoid
enhancer binding factor/T-cell-speciﬁc factor transcrip-
tion factors to activate Wnt target genes (Moon, 2005).
Constitutive epithelial Wnt signaling stimulated prostate
proliferation, regardless of androgen status in
Tgfbr2
fspKO mice. The exogenous neutralization of
canonical Wnt/b-catenin signaling restored both adult
prostate epithelial quiescence and response to castration
in Tgfbr2
fspKO mice (Li et al., 2008; Placencio et al.,
2008). As expected, the control, Tgfbr2
ﬂoxE2/ﬂoxE2 mice
prostate regressed following androgen ablation. How-
ever, the control stromal cells expressed canonical Wnt
ligands (Placencio et al., 2008). Thus, we hypothesized
an endogenous mechanism for antagonizing b-catenin/
Wnt signaling in the prostate epithelia enables castration
responsiveness.
In this study, we sought to explain a mechanism for
castration-dependent prostate regression. b-catenin and
T-cell-speciﬁc 4 (TCF) proteins interact with the AR to
support androgen-dependent transcriptional activity
and promote castration-independent survival and pro-
liferation of prostate epithelia (Truica et al., 2000;
Schweizer et al., 2008; Wang et al., 2008). On the basis
of the data in Xenopus that suggest the protein
hydrogen peroxide-inducible clone 5 (Hic-5) could bind
and antagonize TCF-dependent signaling (Ghogomu
et al., 2006), we focused on this originally described
stromal-speciﬁc protein. The human homolog of Hic-5
was identiﬁed as a TGF-b1-inducible gene that associ-
ates with AR (ARA55) (Shibanuma et al., 1994;
Fujimoto et al., 1999; Heitzer and DeFranco, 2006,
2007). ARA55 expression is elevated during cellular
senescence of normal human ﬁbroblastic cells. Hic-5/
ARA55 binds to and potentates signaling by many
nuclear steroid receptors, including the androgen
receptor (Thomas et al., 1999; Zhang et al., 2000;
Guerrero-Santoro et al., 2004; Shibanuma et al., 2004;
Drori et al., 2005; Heitzer and DeFranco, 2006). In a
surprising ﬁnding, we observed that Hic-5/ARA55 was
expressed in the epithelial compartment of both mouse
and human prostate tissues following androgen depriva-
tion. Experiments of exogenous Hic-5 expression in
LNCaP prostatic epithelia inhibited tumor growth
in vivo and restored regression after androgen ablation
in chimeric tumors of LNCaP epithelia and Tgfbr2-KO
stromal cells. The mechanism elucidated in this study
suggests that epithelial Hic-5/ARA55 represses the Wnt
target, c-myc gene promoter in an androgen-dependent
manner. Further, androgen deprivation potentiated
b-catenin-mediated c-myc activity in prostate epithelia
can be inhibited by Hic-5/ARA55 expression in a TCF4-
dependent and -independent manner.
Results
Hic-5/ARA55 is expressed in prostate epithelia following
castration
TGF-b is upregulated in the prostate following castra-
tion (Kyprianou and Isaacs, 1989; Muir et al., 1994).
Previous reports suggest that the stromal response to
TGF-b supports epithelial regression in a paracrine
manner (Placencio et al., 2008). However, the direct
epithelial response to TGF-b in the microenvironment
has not been clearly identiﬁed. As Hic-5/ARA55 is
induced by TGF-b and an AR cofactor, we examined its
expression in mouse prostates following castration.
Immunohistochemical localization of Hic-5/ARA55 in
intact wild-type C57BL/6 mice indicated exclusive
expression in the prostate stromal compartment, as
previously reported (Heitzer and DeFranco, 2007).
However, 3 and 7 days following castration, Hic-5/
ARA55 was detected in both the epithelial and stromal
compartments (n¼12, Figure 1).
Encouraged by the consistent data in mice, this
ﬁnding was veriﬁed in human prostate tissue. Prostate
cancer and adjacent benign tissue from nine patients had
a mean pathological Gleason score of 6.9±0.6 and
presurgical prostate-speciﬁc antigen (PSA) of 5.0mg/ml
±1.8. The benign and cancer tissues from each patient
were xenografted in contralateral kidneys of two male
severe combined immunodeﬁcient (SCID) mice for 1
Figure 1 Hic-5 expressed in mouse prostate epithelia in response to castration. Hic-5 immunolocalized to the prostate stroma in intact
mice. However, both prostate epithelia and stroma expressed Hic-5 in mice, 3 and 7 days following castration. Scale bar indicates
50mm.
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following castration or the same period of time from
intact mice. All benign and prostate cancer tissue grafts
from intact hosts had only stromal Hic-5/ARA55
expression. Following castration, seven out of nine
grafts had both epithelial and stromal Hic-5/ARA55
expression (Figure 2). Both prostate cancer and benign
tissue had similar patterns of Hic-5/ARA55 expression.
The Fisher’s exact test suggested castration-dependent
Hic-5/ARA55 epithelial expression is signiﬁcant
(P-value¼0.003).
Hic-5 expression in LNCaP cells reduced prostate tumor
growth and restored castrate responsiveness
The novel identiﬁcation of Hic-5/ARA55 in the prostate
epithelia associated with castration-dependent regres-
sion in both mouse and human tissues initiated this
study on its epithelial function. As LNCaP cells do not
express Hic-5, LNCaP cells were made to stably express
Hic-5 (LNCaP-Hic5) by lentiviral transduction. The
expression of Hic-5 protein was conﬁrmed by western
blot analysis (Figure 3a). To determine the role of Hic-5/
ARA55 expression in prostate cancer tumorigenesis and
responsiveness to androgen, we xenografted tissue
recombinants of LNCaP or LNCaP-Hic5 epithelia with
Tgfbr2-ﬂox or Tgfbr2-KO prostate stroma cells. After
the grafts established in 4 weeks, half of the host SCID
mice were castrated. After a further 3 weeks, the
castrated and control host mice were killed. The
representative tumor growth is illustrated and quanti-
tated in Figure 3b and c (n¼6 for each chimeric tumor
group). Parental LNCaP recombinant tumors with
Tgfbr2-KO prostate stromal cells developed tumors
fourfold larger in volume compared with control
recombinants with Tgfbr2-ﬂox prostate stroma cells
(Po0.001). None of the LNCaP/Tgfbr2-ﬂox recombi-
nant grafts in castrated-host mice had detectable
tumors. However, the chimeric LNCaP/Tgfbr2-KO
tumors in intact and castrated-host mice had similar
tumor volumes. These results conﬁrmed our previous
study in Tgfbr2
fspKO mice having castration-resistant
prostate growth (Placencio et al., 2008). Further, there
was no detectible tumor growth in any of the LNCaP-
Hic5/Tgfbr2-ﬂox recombinants. The LNCaP/Tgfbr2-
KO recombinants were 4.4-fold larger than LNCaP-
Hic5/Tgfbr2-KO tumors (Po0.001). Importantly, the
LNCaP-Hic5/Tgfbr2-KO recombinants in castrated-
host mice showed no tumor growth. As the LNCaP-
Hic5 tumors were undetectable in multiple groups in this
study, we repeated the identical experiment in host mice
that were supplemented with testosterone, with expected
greater tumor size (see Supplementary Figure 1).
Regardless of the status of testosterone supplementa-
tion, LNCaP-Hic5 cells had reduced tumor growth.
The chimeric tumor margins differed when associated
with Tgfbr2-ﬂox versus Tgfbr2-KO stromal cells,
although with similar cellular tumor histology
(Figure 4a). The LNCaP and LNCaP-Hic5 cells were
best detected by immunohistochemical localization of
human mitochondria. The Tgfbr2-ﬂox stroma-asso-
ciated tumors had no detectible extracapsular invasion
(Figure 4b). However, the LNCaP/Tgfbr2-KO
recombinant tumors in the intact and castrated hosts
had positively stained LNCaP cells invade into the
kidney parenchyma. In contrast, the LNCaP-Hic5/
Figure 2 Human prostate epithelia expressed ARA55 in response to androgen ablation. ARA55 was localized in the prostate stroma
of benign and cancer tissues xenografted in intact host mice. ARA55 was in addition detected in the epithelial compartment of benign
and cancer prostate tissues harvested from hosts mice following 7 days of castration. Scale bar indicates 50mm.
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which no LNCaP-Hic5 cells were detected in the kidney
parenchyma.
The stark differences in tumor size and invasion
mediated by the stromal TGF-b responsiveness and
epithelial Hic-5 expression, suggested differences in
tumor cell proliferation. To identify mitotic cells, we
performed immunohistochemistry for phosphorylated-
histone 3 (Figure 4c). Correlated with tumor volume,
the quantitation of mitotic cells suggested a signiﬁcant
increase in proliferation when the LNCaP tumors were
associated with Tgfbr2-KO prostate stroma compared
with Tgfbr2-ﬂox stromal cells (Po0.001). Castration
had little effect on proliferation of the LNCaP/Tgfbr2-
KO tumors compared with those in intact mice (Figures
4c and d). LNCaP-Hic5 cells had signiﬁcantly fewer
proliferating cells in Tgfbr2-KO-associated tumors
compared with those LNCaP/Tgfbr2-ﬂox or LNCaP/
Tgfbr2-KO (Po0.001) and most prominently caused a
loss of proliferation following castration (Po0.001).
LNCaP-Hic5 cells were more proliferative than the
parental LNCaP line in culture (data not shown).
However, Hic-5 expression inhibited LNCaP tumor
proliferation in vivo, restored the responsiveness to
castration of LNCaP tumors, otherwise refractile to
castration when associated with Tgfbr2-KO prostate
stroma cells.
The ﬁndings with LNCaP-Hic5 cells were tested in
PC3 prostate cancer cells, which have endogenous
Hic-5/ARA55 expression. Further, PC3–AR cells, with
exogenous expression of AR were tested (Litvinov et al.,
2006a). First, we compared the expression of AR, b-
catenin and Hic-5/ARA55 in LNCaP, LNCaP-Hic5,
PC3 and PC3–AR cells, in vitro, under the conditions of
control, dihydrotestosterone (DHT) and bicalutamide
(Bic) treatment (Supplementary Figure 2). The treat-
ment of LNCaP cells with DHT or Bic did not induce
the expression of Hic-5/ARA55 in vitro. The exogenous
expression of Hic-5/ARA55 in LNCaP cells was 1.5-fold
of the physiological expression level in PC3 cells.
Interestingly, exogenous AR expression in PC3 cells
signiﬁcantly reduced Hic-5/ARA55 expression. The
expression level of b-catenin was consistent in all the
cells, regardless of treatment. Tissue recombination of
PC3 with Tgfbr2-Flox and Tgfbr2-KO prostate stromal
cells similarly developed large castrate-resistant tumors
(Supplementary Figure 3). However, no tumor growth
was detected in recombinants of PC3–AR cells with
either of the prostate stromal cell type (Supplementary
Figure 3). Thus, we focused on LNCaP and LNCaP-
Hic5 cells for further Hic-5/ARA55 mechanistic studies
on tumor growth and castration dependence.
Hic-5 antagonizes c-myc activity
Upregulation of epithelial Wnt signaling in human and
Tgfbr2
fspKO mouse model has been associated with
increased tumorigenicity and castrate-independent re-
sponse in prostate cancer cells (Li et al., 2008; Placencio
et al., 2008; Wang et al., 2008). Thus, the role of
epithelial Hic-5 expression in response to castration was
explored in terms of regulation of the Wnt pathway. We
initially veriﬁed the AR–coactivator function of Hic-5
using the PSA luciferase reporter. DHT treatment
resulted in a tenfold PSA luciferase activity induction
in LNCaP cells compared with control, and a further 23-
fold induction in LNCaP-Hic5 cells (Figure 5a;
Po0.001). The coexpression of constitutively active
b-catenin (S37Y mutant) doubled PSA reporter activity
over control in the presence or absence of Hic-5
Figure 3 Hic-5 inhibited LNCaP tumorigenicity and restored responsiveness to castration. (a) western blot indicated no Hic-5
expression in LNCaP cells, but strong Hic-5 expression in LNCaP-Hic5 cells. (b) Representative images of chimeric tumors generated
from LNCaP and LNCaP-Hic5 epithelia recombined with either Tgfbr2-ﬂox or Tgfbr2-KO mouse prostate stromal cells in intact or
castrated (Cx) SCID host mice. Scale bar indicate 3mm. (c) The tumor volumes were quantitated. ANOVA analysis suggested
signiﬁcant differences in LNCaP/Tgfbr2-KO tumors from intact (In) and castrated (Cx) mice compared with other recombinants
(n¼48, Po0.001). However, the growth of LNCaP/Tgfbr2-KO tumors had no signiﬁcant difference in intact and castrated-host mice.
The following chimeric tumors had no detectible growth: intact host mice with LNCaP-Hic5/Tgfbr2-ﬂox recombinants and castrated-
host mice with LNCaP/Tgfbr2-ﬂox, LNCaP-Hic5/Tgfbr2-ﬂox and LNCaP-Hic5/Tgfbr2-KO recombinants. A red horizontal line
indicated the mean of six calculated tumor volumes per group.
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expression of b-catenin had little effect on PSA
luciferase activity. We speculated the signiﬁcant increase
of PSA luciferase activity by Hic-5 was because
of induced AR expression in LNCaP-Hic5 cells, how-
ever, both western and immunohistochemistry analyses
showed no difference in AR expression level
(Supplementary Figure 2), and location between LNCaP
and LNCaP-Hic5 cells (data not shown). As expected,
Bic and DHT had respective inhibitory and stimulatory
effects on PSA luciferase activity. Hic-5 expression
further potentiated PSA luciferase activity by DHT
Figure 4 Hic-5 expression inhibited LNCaP recombinant tumor invasion and restored responsiveness to castration. (a)
Representative H and E staining of the tissue recombinants xenografted under the renal capsule indicated areas of vascularity and
graft/kidney interface. Note that no tumors were detected in LNCaP-Hic-5/Tgfbr2-ﬂox recombinants from intact or castrated-host
mice. ‘K’ indicates host SCID mice kidney tissue. (b) Immunohistochemistry of human mitochondrial marker distinguished the
LNCaP and LNCaP-Hic-5 tumor epithelia from the mouse tissue. The LNCaP/Tgfbr2-ﬂox and LNCaP-Hic5/Tgfbr2-KO chimeric
tumors had distinct tumor margins (uninterrupted dashed line). The LNCaP/Tgfbr2-KO chimeric tumors invaded the host kidney
under both intact and castration conditions (arrows). (c) Immunohistochemistry of phosphorylated-histone H3 was performed and
cells undergoing mitosis were identiﬁed. Scale bar indicates 50mm for panels (a–c). (d) The mitotic cells determined by phosphorylated-
histone H3 staining were quantitated for each chimeric tumor in intact and castrated-host mice. No positive cells were found in the
groups without any tumor growth. ANOVA signiﬁcant differences of *Po0.05 and ***Po0.001 were identiﬁed.
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as previously reported (Fujimoto et al., 1999).
Next, the effect of Hic-5 regulation on canonical Wnt
target gene reporter, c-myc-luciferase construct, was
tested under the same conditions of the PSA luciferase
assay (Figure 5b). Bic, DHT treatment alone or Hic-5
expression in LNCaP cells did not affect the c-myc
luciferase activity. The exogenous expression of S37Y–
b-catenin upregulated c-myc reporter activity in LNCaP
cells sixfold over control (Po0.001) and was further
enhanced twofold by the supplementation of DHT
(Po0.001). However, the expression of Hic-5 inhibited
c-myc luciferase activity induced by b-catenin
(Po0.001).
Previously we published that elevated Wnt ligands
expression by Tgfbr2
fspKO prostate stromal cells promote
prostate tumorigenesis and by Tgfbr2-ﬂox prostate
stromal cells following Bic treatment (Li et al., 2008;
Placencio et al., 2008). Note, that most Wnt ligands of
mouse can bind to frizzled receptors of human origin.
Further we found that Wnt3a neutralizing antibody
could inhibit c-myc reporter activity and block LNCaP
cell proliferation, induced by conditioned media from
Tgfbr2-KO mouse prostate stromal cells (Li et al.,
2008). We tested the role of Tgfbr2-ﬂox and Tgfbr2-KO
prostate stromal cell-derived factors on myc-reporter
activity in LNCaP and LNCaP-Hic5 cells, by incubation
with stromal-conditioned media. In LNCaP cells, the
activation of c-myc luciferase reporter was elevated 2.6-
fold when the cells were treated with Tgfbr2-KO
stromal-conditioned media compared with that of
Tgfbr2-ﬂox stromal cells (Po0.05, Figure 5c). No
signiﬁcant induction of c-myc luciferase activity was
observed in LNCaP-Hic5 cells with conditioned media
from Tgfbr2-ﬂox or Tgfbr2-KO stromal cells (P40.05).
Together, expression of Hic-5 inhibited the direct and
paracrine-mediated c-myc activation in prostate epithelia.
Hic-5 inhibits c-myc gene by forming a suppressor
complex
We next chose to identify how Hic-5 affected endogen-
ous canonical Wnt transcriptional target, c-myc, in the
context of androgen signaling agonists and antagonists.
Chromatin immunoprecipitation (ChIP) and sequential
ChIP analyses were performed on the human c-myc
promoter in LNCaP and LNCaP-Hic5 cells. The c-myc
promoter has two closely spaced TCF binding elements
at  1156bp TCF4 binding element (TBE1) and  589bp
(TBE2); each account for 50% of c-myc gene activation
when b-catenin binds to TCF4 on the DNA (He et al.,
1998). We observed similar occupancy of the transcrip-
tional complex on these TBE1 and TBE2. The
sequential ChIP experiments represented in this study
were for the TBE2 c-myc promoter region (Figure 6).
The speciﬁcity of ChIP and sequential ChIP analysis
were conﬁrmed by pull–down assay with normal mouse
immunoglobulin G (Figures 6 and 7) and PCR
ampliﬁcation with exon 2 of c-myc gene (Figure 7).
(Supplementary Figure 4 illustrates full gel images of the
ChIP and sequential ChiP assays in Figure 6.) First,
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Figure 5 Hic-5 coactivated AR- and inhibited c-myc-transcrip-
tional activity. (a) Luciferase reporter assay for the PSA promoter
indicated androgen transcriptional activity of LNCaP (empty bars)
and LNCaP-Hic5 (ﬁlled bars) cells under control (vehicle treated),
bicalutamide (10
 5 M Bic), dihydrotestosterone (10
 8 M DHT)
treatment and/or cotransfected with constitutively active S33Y
b-catenin (b-cat). (b) Canonical Wnt signaling was measured by the
c-myc promoter luciferase reporter assay in LNCaP and LNCaP-
Hic5 cells under the same conditions as in panel A. (c) C-myc
luciferase assays was performed on LNCaP and LNCaP-Hic5 cells
following incubation with conditioned media from Tgfbr2-ﬂox or
Tgfbr2-KO prostate stromal cells. Data shown in panels (a–c)i s
representative of at least three separate experiments performed in
triplicate. The luciferase activities are normalized to protein
concentration. ANOVA signiﬁcant differences of **Po0.01, and
***Po0.001 were identiﬁed.
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OncogeneTCF4 occupation of the c-myc promoter in LNCaP and
LNCaP-Hic5 cells were similar, regardless of treatment
conditions. The coincident binding of TCF4 and
b-catenin on the TBEs, suggestive of c-myc gene
activation was prominent following either Bic or DHT
treatment in LNCaP cells in subsequent sequential ChIP
analysis. LNCaP-Hic5 cells had no coincident TBE
binding of TCF4 and b-catenin under any treatment
condition. In further effort to delineate how Hic-5
inhibited c-myc gene transcription, we found TBEs
occupied by AR through TCF4 in LNCaP cells with Bic
and DHT treatment. In LNCaP-Hic5 cells, only control
conditions had cooperative occupation of AR and
TCF4 on the c-myc promoter. Sequential ChIP analyses
indicate Hic-5 occupancy of TCF4/TBEs under control
and DHT-treated conditions in LNCaP-Hic5 cells, but
not after Bic treatment. Thus, Hic-5 inhibited c-myc
activity by binding with TCF4 on the TBEs in the
promoter to prevent activation by b-catenin.
Owing to the apparent differences in mechanism of
c-myc transcriptional inhibition by Hic-5/ARA55 with
Bic and DHT treatment, the possibility of Hic-5/ARA55
binding TBEs, independent of TCF4 was explored. We
conducted individual ChIP analysis for TBEs of the
c-myc promoter with antibodies for AR, b-catenin or
Hic-5. The ChIP qPCR results were averaged for TBE1
and TBE2 to ease presentation (Figure 7). As previously
reported, the individual ChIP results of AR and
b-catenin were similar to that detected in the sequential
ChIP analysis with TCF4, to suggest that AR and
b-catenin associates with TBEs through TCF4 on the
c-myc promoter (Truica et al., 2000). However, the
individual ChIP of Hic-5 revealed the greatest TBE
binding following Bic treatment, compared with that of
control and DHT. This suggested that Hic-5 binds to
TBEs on the c-myc promoter independent of TCF4 in
the situations of androgen ablation by Bic. Thus, the
suggested mechanism of Hic-5 inhibition of c-myc
activation were through Hic-5/AR or Hic-5 exclusion
of b-catenin binding with TCF4 on TBEs under control
or DHT treatment, respectively, or through Hic-5
directly occupation of TBEs instead of TCF4 in the
present of Bic.
Discussion
The role of Hic-5/ARA55 in stromal AR-mediated gene
expression has been identiﬁed as a coactivator and was
therefore initially suggested to promote prostate cancer
cell growth (Rahman et al., 2003; Fujimoto et al., 2007).
However, more recently Hic-5/ARA55 was reported
inhibiting the androgen responsive for keratinocyte
growth factor (Heitzer and DeFranco, 2007). The link
of Hic-5/ARA55 to prostate cancer has been debated
(Fujimoto et al., 2001, 2007; Mestayer et al., 2003;
Miyoshi et al., 2003). In whole prostate tissue extracts,
Hic-5/ARA55 expression was decreased when asso-
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Figure 6 Hic-5 and TCF4 co-occupy the c-myc promoter in an androgen-dependent manner. LNCaP and LNCaP-Hic5 cells were
treated with vehicle (con), DHT (10
 8 M) or Bic (10
 5 M) for 3h. PCR products in the input panel were ampliﬁed using diluted
chromatin that was not immunoprecipitated. Preimmune mouse IgG was used to detect nonspeciﬁc immunoprecipitated DNA.
PCR products shown in gel are representatives of three separate experiments.
TBE Exon 2
Con Bic DHTCon Bic DHT
LNCaP LNCaP
Con Bic DHTCon Bic DHT
LNCaP-Hic5
*
Con Bic DHT
2
1
0
Input
Hic-5
IgG
LNCaP-Hic5
Figure 7 Hic-5 binds to the TBEs of the c-myc promoter in the
presence of bicalutamide. The chromatin–protein complexes were
pulled down by antibody for Hic-5. (a) PCR products in the input
panel were ampliﬁed using diluted chromatin that was not
immunoprecipitated. A mouse IgG was used to detect any
nonspeciﬁc immunoprecipitated DNA. PCR products shown in
gel are representatives of three separate experiments. (b) Relative
changes in Hic-5 recruitment to the TBEs of c-myc promoter were
quantitated by real-time qPCR, normalized by the input. Data are
shown as an average of TBE1 and TBE2 binding of at least three
independent experiments. ANOVA signiﬁcant differences of
**Po0.05.
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Oncogeneciated with prostate cancer, compared with benign tissue
(Mestayer et al., 2003). However, this ﬁnding is likely
not reﬂective of expression levels, as the ratio of stroma
to epithelia also decreases in prostate cancer (Ayala
et al., 2003). Immunohistochemical localization of Hic-
5/ARA55 in benign and prostate cancer-associated
stromal compartment was similar in human tissues
(Figure 2). Previous reports suggest Hic-5/ARA55
expression contribute to prostate stromal responsiveness
to androgens and mediates adjacent epithelial differ-
entiation and growth (Heitzer and DeFranco, 2006).
The ﬁrst in vivo indication of Hic-5/ARA55 epithelial
expression was found in the mouse and human prostate
tissues following castration of host mice (Figures 1 and
2). This was an especially interesting ﬁnding as Hic-5/
ARA55 regulates both TGF-b and AR activity—two
established signaling pathways critical for prostate
regression on castration. We had previously reported
that mouse prostate stromal cells express Wnt ligands
following castration or Bic treatment in vitro (Placencio
et al., 2008). The paracrine activation of Wnt/b-catenin
signaling in prostate epithelia contributes to epithelial
survival following castration (Placencio et al., 2008). As
prostates and prostate cancer normally respond to
castration (at least initially), the observed Hic-5/
ARA55 expression in the epithelia may be a means of
inhibition of Wnt, speciﬁcally the c-myc gene at the
chromatin level, to enable regression. On the basis of
potential TCF4 repressor function of Hic-5/ARA55 for
Wnt target genes in Xenopus development (Ghogomu
et al., 2006), we hypothesized Hic-5/ARA55 could
antagonize canonical Wnt signaling in human prostate
tumorigenesis and regression in response to castration.
The activation of Wnt/b-catenin signaling is observed
in 90% of human prostate cancer clinical samples, with
upregulation of Wnt-responsive genes such as c-myc and
Twist (Kwok et al., 2005; Gurel et al., 2008). The
suppression of Wnt/b-catenin signaling inhibits prostate
cancer progression and castration-resistant prostate
cancer growth (Wang et al., 2008; Lu et al., 2009). The
data in this study would support epithelial Hic-5
expression inhibit c-myc activity, an inherent response
to androgen ablation (Placencio et al., 2008). However,
immunohistochemistry for Hic-5/ARA55 also did not
show elevation in LNCaP xenografts, following castra-
tion of host mice. As LNCaP cells do not express the
TGF-b type II receptor (Guo and Kyprianou, 1999),
and Hic-5 is a TGF-b1-dependent gene (Fujimoto et al.,
1999), it was not surprising that Hic-5/ARA55 expres-
sion was not found in the LNCaP cells in vitro or in vivo.
Stromal–epithelial interactions are critical in prostate
development and tumorigenesis. The previously gener-
ated Tgfbr2
fspKO mice developed prostatic intraepithelial
neoplasia lesions, with elevated expression of the Wnt
target gene, c-myc in the epithelium (Bhowmick et al.,
2004). More recent studies revealed Tgfbr2
fspKO mice
develop prostate adenocarcinoma (Li et al., 2008). Of
the differentially regulated paracrine factors resulting
from the TGF-b receptor knockout in the prostate
stroma, Wnt3a was shown to be critical for tumor
growth. Importantly, the Tgfbr2
fspKO model resembles
the clinical situation, in which 69% of the human
prostate cancer tissues lose TGF-b type II receptor
stromal expression (Li et al., 2008). Thus, the chimeric
prostate tumors of control, Tgfbr2
ﬂoxE2/ﬂoxE2 and
Tgfbr2
fspKO prostate stroma cells with LNCaP epithelia,
provided a relevant recombinant model for prostate
cancer. We had previously observed that Tgfbr2-KO
prostate stroma cells promote approximately four fold
greater LNCaP tumor growth in vivo than Tgfbr2-ﬂox
stromal cells (Li et al., 2008). Notably, the prostate
cancer derived-LNCaP cells rarely develop tumors in
subcutaneous or subrenal capsule grafts unless they are
recombined with stromal ﬁbroblasts (Gleave et al.,
1991). In this study, we discovered that Hic-5 expression
in LNCaP cells decreased Tgfbr2-KO ﬁbroblast-asso-
ciated recombinant tumor growth near to that observed
with control stromal cells (Figure 3b and Supplementary
Figure 1). Further, we observed signiﬁcant regression of
LNCaP-Hic5/Tgfbr2-KO tumors following castration
(Figure 3b). The gross chimeric tumor size in intact and
castrated-host mice directly correlated with the number
of cells undergoing mitosis (Figures 3c and 4d). The
stromal regulation of tumor size, proliferation and
androgen responsiveness was dependent on epithelial
Hic-5 expression. Together, it would suggest epithelial
expression of Hic-5/ARA55 supports castration respon-
siveness, but the dominant role of prostate androgen
responsiveness remains in the stromal compartment
(Cunha, 2008; Placencio et al., 2008).
Epithelial Hic-5 expression prevented invasion of the
LNCaP tumors. Interestingly, the highly metastatic
prostate cancer cell line, PC3, has high Hic-5/ARA55
expression (Mestayer et al., 2003). Silencing Hic-5/
ARA55 in prostate epithelial, DU145, cells inhibit TGF-
b-mediated epithelial to mesenchymal transdifferentia-
tion (Mestayer et al., 2003). In human breast epithelia,
MCF10A, Hic-5/ARA55 promotes TGF-b-mediated
epithelial to mesenchymal transdifferentiation through
the downregulation of E-cadherin (Tumbarello and
Turner, 2007). Thus, it has been suggested that ectopic
expression of Hic-5/ARA55 in prostate carcinoma may
stimulate tumor cell migration and invasion (Wang
et al., 2008). On the contrary, this in vivo study
conﬁrmed in cells that have intact androgen signaling,
exogenous expression of Hic-5 inhibited tumor invasion
of LNCaP cells. It is noteworthy that the proliferation
and tumorigenesis in AR-deﬁcient PC3 is signiﬁcantly
diminished when AR is overexpressed as reported before
and this study in the recombination with prostate
stroma cells (Litvinov et al., 2006a, 2006b; Niu et al.,
2008). Hic-5/ARA55 was previously reported to inhibit
both Smad3 (TGF-b signaling mediator) and Smad7
(TGF-b signaling antagonist) through direct protein–
protein interaction (Wang et al., 2005, 2008). Wang
et al. suggested that the net result of blocking both
Smad3 and Smad7 by Hic-5/ARA55 was likely
associated with Smad2 transcriptional activity in stro-
mal ﬁbroblasts. Thus, similar Smad2-speciﬁc signals
could be promoted in the prostate epithelia during
prostate regression. However, the parental LNCaP cells
do not respond to TGF-b (Jakowlew et al., 1997; Zhu
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Oncogeneet al., 2008). Hence, the lack of observed tumor invasion
by LNCaP-Hic5 cells might be due to the inhibition of
Wnt/b-catenin signaling, prominently associated prolif-
eration and epithelial to mesenchymal transdifferentia-
tion promotion.
To better understand the mechanism of Hic-5/ARA55
inhibition of c-myc activity in prostate epithelia, the
results from luciferase, ChIP and sequential ChIP
analyses need to be considered together. The inhibition
of c-myc luciferase activity by Hic-5 expression in
LNCaP cells and Hic-5 occupation of TBEs on c-myc
promoter through TCF4 or directly would suggest, Hic-
5 is a transcriptional suppressor of Wnt target genes by
binding DNA directly or as Hic-5/TCF4 or Hic-5/AR/
TCF4 complex in an androgen-dependent manner
(Figures 5, 6 and 7). Interestingly, we found DHT
stimulated b-catenin-induced c-myc luciferase activity in
LNCaP cells. There are reports of DHT inhibiting
TOPFlash (TCF/b-catenin) activity (not c-myc reporter)
in the presence of androgen receptor expression (Chesire
and Isaacs, 2002; Mulholland et al., 2003; Schweizer
et al., 2008). Apart from the different reporter construct
used, other cell lines such as SW480 cells (with a mutant
antigen-presenting cells) (Chesire and Isaacs, 2002; Kaur
et al., 2010), PC3 cells (with no exogenous b-catenin
expression) (Mulholland et al., 2003) were the basis of
their conclusions. As no one cell line can model the
in vivo situation of stromal–epithelial interaction, we
relied on the castration response, mouse and human
prostate tissues demonstrated for the basis of the further
mechanistic studies on Hic-5/ARA55. It is provocative
to think that Hic-5/ARA55 expression may be a means
of increasing sensitivity to ultralow concentrations of
androgens in AR antagonist-treated patients (Rahman
et al., 2003). However, we found that Hic-5 can inhibit
c-myc in TCF4-dependent and independent mechani-
sms. Hic-5/ARA55 expression in prostate epithelia
enables prostate regression in the absence of androgens.
A future direction in prostate cancer therapeutics could
involve combination treatment of androgen ablation
and Hic-5/ARA55 protein or Hic-5/ARA55 mimics.
Such therapy could eliminate a population of castration-
resistant prostate cancers cells. Hic-5/ARA55 is a
multifunctional protein interacting with multiple hor-
mone receptors, as well as in focal adhesion complex
proteins that shuttle between the cytoplasm and nucleus.
This study identiﬁed the novel role for Hic-5/ARA55 on
c-myc promoter activation through its interactions with
TCF4 and AR. The role of Hic-5/ARA55 on other
hormone receptors and cell–cell interactions would be
important future studies.
Materials and methods
Human tissues
Prostate cancer and adjacent benign tissue were separated
from fresh radical prostatectomy samples from patients
undergoing surgery at Vanderbilt University Medical Center
in 2009. Patients who had undergone hormone ablation
therapy before surgery were excluded. All subjects were
annotated based on age, presurgical serum PSA, pathological
Gleason score, pathological stage, extracapsular involvement
and surgical margin status (Supplementary Table). All samples
were deidentiﬁed according to the Institutional Review Board,
Vanderbilt University.
Animals
Tgfbr2
ﬂoxE2/ﬂoxE2 and Tgfbr2
fspKO mice bred on the C57BL/6
background were generated and maintained as previously
described (Bhowmick et al., 2004). Adult male SCID mice and
C57BL/6 mice were purchased from Harlan (Indianapolis, IN,
USA). Vanderbilt Institutional Animal Care and Use
Committee approved the animal procedures.
Cell culture
Primary mouse prostate stromal cell cultures were generated
from 6- to 8-week-old Tgfbr2
ﬂoxE2/ﬂoxE2 or Tgfbr2
fspKO mice as
described before (Li et al., 2008). Prostate stromal ﬁbroblastic
cells derived from Tgfbr2
ﬂoxE2/ﬂoxE2 and Tgfbr2
fspKO mice are
termed Tgfbr2-ﬂox and Tgfbr2-KO, respectively.
LNCaP, PC3 cells were purchased from ATCC (Manassas,
VA, USA). LNCaP-Hic5 cells were generated by lentivirus
transduction of parental LNCaP cells with Hic-5 cDNA,
according to manufacturer directions (Invitrogen, Carlsbad,
CA, USA). PC3–AR cells were derived from PC3 cells (Dr
John T Isaacs, Johns Hopkins University). In the experiments
with dihydrotestosterone DHT and Bic treatment, the cells
were cultured in phenol red-free RPMI medium with 10%
charcoal-stripped fetal bovine serum to reduce steroids from
the media.
Tissue recombination and subrenal capsule xenografting
Tissue recombinants were generated by combining 100000
prostate cancer epithelia with 250000 Tgfbr2-ﬂox or Tgfbr2-
KO prostatic stromal cells in 50ml of rat-tail collagen. The
tissue recombinants were grafted under the renal capsule of
SCID mice as previously described (Li et al., 2008). At 4 weeks
following grafting, half of the host SCID mice were castrated
for an additional 3 weeks. After a total 7 weeks following
grafting, the mice were killed. The grafts were then removed,
photographed and processed for histology evaluation. The
tumors were measured and the volume calculated by the
formula: volume¼width length 0.52 using Image J pro-
gram (developed by National Institutes of Health). It is
noteworthy that the formula underestimates the volume of
invasive tumors, and accordingly underestimates differences
between small noninvasive and larger invasive tumors.
Statistical signiﬁcance of results was determined by analysis
of variance.
Live human prostate tissues were grafted under the renal
capsule of male SCID mice supplemented with testosterone-
containing silastic tubing. Following 1 week of grafting, the
host mice were either left intact or castrated, and the silastic
tubing removed for an additional 7 days. All grafts were
collected and histochemically evaluated 14 days following
xenografting.
Immunohistochemistry
Immunohistochemical staining on parafﬁn-embedded tissue
sections (5mm) were conducted using antibodies against:
phosphorylated-histone H3 (1:1000, Millipore, Billerica, MA,
USA), and human mitochondria (1:100, Millipore). Appro-
priate HRP-conjugated secondary antibodies and DAB
incubation (Dako North America, Carpinteria, CA, USA) was
used for visualization. All sections were nuclear counter-stained
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Oncogenewith Hematoxylin Gill3 (Fisher, Pittsburgh, PA, USA). All
slides were photographed on a Nikon Coolscope (Nikon
instruments, Lewisville, TX, USA).
Transfection and luciferase assay
Prostate cancer cells were transfected with the PSA (Lee et al.,
2000) or c-myc (He et al., 1998) reporter luciferase construct,
alone or together, with constitutive active b-catenin (S37Y)
cDNA construct using Lipofectamine LTX (Invitrogen),
according to the manual. Next day, the cells were treated
with DHT, Bic or with conditioned media from primary
cultured Tgfbr2
ﬂoxE2/ﬂoxE2 or Tgfbr2
fspKO mice prostate stromal
cells for 24h before the cells were collected and analyzed for
ﬁreﬂy luciferase activity, normalized to protein concentration.
Statistical signiﬁcance of results was determined by analysis of
variance.
The PSA luciferase construct contains an enhancer region of
PSA from  5824 to  3738 with three AREs and promoter
regions of PSA from  320 to þ12 with one ARE (Dr Robert
Matusik, Vanderbilt University). The positive and negative
controls in the PSA–luciferase experiments were the addition
of DHT and Bic, respectively. The c-myc luciferase construct
contains a 2.5kb region of the c-myc promoter, which includes
two TCF4 binding elements and two antigen-presenting cell-
responsive regions (Dr Bert Vogelstein, The Johns Hopkins
Oncology Center). The transfection of constitutive active
b-catenin was the positive control for the activation of the
c-myc-luc reporter.
Chromatin immunoprecipitation
Prostate cancer, LNCaP and LNCaP-Hic5 cells were treated
3h with DHT or Bic before crosslinking, lysis and sonication,
as described previously (Li et al., 2008). Chromatin fragments
were immunoprecipitated with TCF4, b-catenin, AR or Hic-5/
ARA55 antibodies (Santa Cruz, Santa Cruz, CA, USA) or
preimmune mouse immunoglobulin G overnight at 41C. After
immunoprecipitation, protein G agarose was added into each
reaction tube to pull down the chromatin/protein–antibody
complex as indicated by the EZ ChIP kit (Millipore). For
sequential ChIPs, complexes immunoprecipitated with anti-
TCF4 were eluted by incubation with 10mM dithiothreitol for
10min at 371C in ChIP dilution buffer, followed by
reimmunoprecipitation with antibodies for AR, b-catenin,
Hic-5/ARA55 or immunoglobulin G. PCRs were performed
with 2ml puriﬁed DNA for 30 cycles of ampliﬁcation. The
primers for the TBEs of the c-myc promoter were forward: 50-GT
GGCAATGCGTTGCTGGGTTATT-30, reverse: 50-ATAAA
TCATCGCAGGCGGAACAGC-30 for TBE1; and forward:
50-ACGTTTGCGGGTTACATACAGTGC-30,r e v e r s e :5 0-GA
GTCAGCAGAGACCCTTGTGAAA-30 for TBE2. The for-
ward primer 50-CCCTCAACGTTAGCTTCACCAACA-30,
and reverse primer 50-GCAGCAGCTCGAATTTCTTCCA
GA-30 for the internal region (exon 2) of c-myc were used as
negative control. The quantiﬁcation of precipitated-TCF4
binding site between groups was analyzed by DDCt method,
and normalized by input for the single ChIP and immunoglo-
bulin G for the sequential ChIP. Statistical signiﬁcance was
determined by analysis of variance. The ﬁnal PCR ampliﬁed-
TBE fragments were also run on 1% agarose gels and
visualized by ethidium bromide.
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